1
Ixazomib + Pomalidomide + Dexamethasone In MM
Condition(s):Multiple Myeloma; Multiple Myeloma in RelapseLast Updated:April 19, 2023Recruiting
Multiple Myeloma in Relapse: 1334 Clinical Trials, Page 1 of 134
Hide Studies Not Open or Pending
2
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:September 5, 2021Completed
3
Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:August 21, 2019Unknown status
4
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:March 1, 2023Active, not recruiting
5
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:February 1, 2023Recruiting
6
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:February 21, 2023Active, not recruiting
7
Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:December 10, 2018Unknown status
8
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:May 8, 2023Recruiting
9
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:February 15, 2022Completed
10
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:July 31, 2015Terminated